Issues spotlight: Medical cannabis

Issues spotlight: Medical cannabis 779904 CPHXXX10.1177/1715163518779904C P J / R P CC P J / R P C research-article2018 CP hA CONNECTION CPhA ConneCtion of cannabis, including participating in the Task CPhA’s position Force on Cannabis Legalization and Regulations As medication experts, pharmacists are best and appearing before the House of Commons equipped to provide clinical advice to patients Standing Committee on Health. Throughout and appropriate oversight in the safe manage- each consultation, we emphasized how pro- ment and dispensing of medical cannabis. Phar- posed legislation could ae ff ct patients relying on macists have the necessary expertise to help medical cannabis as part of their drug therapy manage potential risks associated with medi- regimen. CPhA also oer ff ed statements and com- cal cannabis, including adverse effects, harmful mentary throughout 2016 and 2017 as the federal drug interactions, contraindications and poten- government debated the proposed regulations. tial addictive behaviour. Pharmacists also have Education and practice tools: CPhA has the existing infrastructure in place to handle developed a number of resources to help phar- controlled substances, as well as a secure sup- macists provide effective medication manage- ply chain to limit diversion. CPhA believes that ment for their patients using medical cannabis, pharmacist management and dispensing of including the following: medical cannabis is the best option to strengthen any future framework, improve access and pro- • Online CE programs: “An Introduction to tect patient and public safety. With governments Medical Cannabis and Cannabinoids” and moving to pass regulations and prepare for legal- “Medical Cannabis: Applying the Evidence ization in 2018, CPhA has consistently stressed to Practice” are oer ff ed free of charge to the need to maintain a robust medical canna- members of provincial pharmacy associa- bis stream and improve patient care and safety tions and Association of Faculties of Phar- through pharmacist dispensing. macy of Canada (AFPC) • Medical Cannabis FAQ Overview of CPhA activities • Cannabis for Medical Purposes Evidence Independent research: In February 2016, CPhA Guide commissioned Abacus Data to survey Canadi- CPhA continues to work on this file and is ans on their perceptions and attitudes towards committed to working with governments to marijuana. In March 2016, CPhA commissioned mitigate risk and enhance safety for Canadians. KPMG research into the key benefits that could Additional education and practice tools will be be expected from pharmacist management and released throughout 2018 to support pharma- dispensing of medical cannabis. cists across Canada. For more information on Government submissions: Over the past 2 CPhA’s efforts on medical cannabis, please visit years, CPhA has been actively involved in the www.pharmacists.ca/cannabis. ■ government’s consultations on the legalization © The Author(s) 2018 DOI: 10.1177/1715163518779904 CPJ/RPC • MONTH / MONTH 2018 • VOL XX, NO X 1 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Canadian Pharmacists Journal / Revue des Pharmaciens du Canada SAGE

Issues spotlight: Medical cannabis

Free
1 page

Loading next page...
1 Page
 
/lp/sage/issues-spotlight-medical-cannabis-wVO00LAdJW
Publisher
SAGE Publications
Copyright
© The Author(s) 2018
ISSN
1715-1635
eISSN
1913-701X
D.O.I.
10.1177/1715163518779904
Publisher site
See Article on Publisher Site

Abstract

779904 CPHXXX10.1177/1715163518779904C P J / R P CC P J / R P C research-article2018 CP hA CONNECTION CPhA ConneCtion of cannabis, including participating in the Task CPhA’s position Force on Cannabis Legalization and Regulations As medication experts, pharmacists are best and appearing before the House of Commons equipped to provide clinical advice to patients Standing Committee on Health. Throughout and appropriate oversight in the safe manage- each consultation, we emphasized how pro- ment and dispensing of medical cannabis. Phar- posed legislation could ae ff ct patients relying on macists have the necessary expertise to help medical cannabis as part of their drug therapy manage potential risks associated with medi- regimen. CPhA also oer ff ed statements and com- cal cannabis, including adverse effects, harmful mentary throughout 2016 and 2017 as the federal drug interactions, contraindications and poten- government debated the proposed regulations. tial addictive behaviour. Pharmacists also have Education and practice tools: CPhA has the existing infrastructure in place to handle developed a number of resources to help phar- controlled substances, as well as a secure sup- macists provide effective medication manage- ply chain to limit diversion. CPhA believes that ment for their patients using medical cannabis, pharmacist management and dispensing of including the following: medical cannabis is the best option to strengthen any future framework, improve access and pro- • Online CE programs: “An Introduction to tect patient and public safety. With governments Medical Cannabis and Cannabinoids” and moving to pass regulations and prepare for legal- “Medical Cannabis: Applying the Evidence ization in 2018, CPhA has consistently stressed to Practice” are oer ff ed free of charge to the need to maintain a robust medical canna- members of provincial pharmacy associa- bis stream and improve patient care and safety tions and Association of Faculties of Phar- through pharmacist dispensing. macy of Canada (AFPC) • Medical Cannabis FAQ Overview of CPhA activities • Cannabis for Medical Purposes Evidence Independent research: In February 2016, CPhA Guide commissioned Abacus Data to survey Canadi- CPhA continues to work on this file and is ans on their perceptions and attitudes towards committed to working with governments to marijuana. In March 2016, CPhA commissioned mitigate risk and enhance safety for Canadians. KPMG research into the key benefits that could Additional education and practice tools will be be expected from pharmacist management and released throughout 2018 to support pharma- dispensing of medical cannabis. cists across Canada. For more information on Government submissions: Over the past 2 CPhA’s efforts on medical cannabis, please visit years, CPhA has been actively involved in the www.pharmacists.ca/cannabis. ■ government’s consultations on the legalization © The Author(s) 2018 DOI: 10.1177/1715163518779904 CPJ/RPC • MONTH / MONTH 2018 • VOL XX, NO X 1

Journal

Canadian Pharmacists Journal / Revue des Pharmaciens du CanadaSAGE

Published: Jun 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off